Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Net Cash Flow (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Net Cash Flow for 7 consecutive years, with -$11.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 109.93% to -$11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.0 million through Dec 2025, up 270.58% year-over-year, with the annual reading at $11.0 million for FY2025, 270.58% up from the prior year.
  • Net Cash Flow hit -$11.2 million in Q4 2025 for Eton Pharmaceuticals, down from $11.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $11.7 million in Q3 2025 to a low of -$11.2 million in Q4 2025.
  • Historically, Net Cash Flow has averaged $197500.0 across 5 years, with a median of $663500.0 in 2022.
  • Biggest five-year swings in Net Cash Flow: surged 22812.5% in 2022 and later tumbled 680.79% in 2024.
  • Year by year, Net Cash Flow stood at -$8.3 million in 2021, then surged by 135.25% to $2.9 million in 2022, then plummeted by 123.3% to -$682000.0 in 2023, then crashed by 680.79% to -$5.3 million in 2024, then crashed by 109.93% to -$11.2 million in 2025.
  • Business Quant data shows Net Cash Flow for ETON at -$11.2 million in Q4 2025, $11.7 million in Q3 2025, and $8.0 million in Q2 2025.